AliveCor Files ITC Complaint Seeking to Bar U.S. Importation of Apple Watch
Mountain View, CA, April 20, 2021 – AliveCor, the global leader in FDA-cleared personal electrocardiogram (ECG) technology and services, today announced that it has filed a complaint with the U.S. International Trade Commission (ITC), alleging Apple’s infringement of three AliveCor patents. Starting in 2011, AliveCor has invested heavily in bringing advanced, AI-powered cardiological detection technology to consumer users. These investments have produced unique, market changing products including:
- KardiaMobile, the most clinically-validated personal ECG in the world
- KardiaMobile 6L, the first and only six-lead personal ECG KardiaBand, the first FDA-cleared medical device accessory for Apple Watch
- SmartRhythm, revolutionary artificial intelligence that continuously evaluates heart activity for signs of arrhythmias
In December 2020, AliveCor filed a federal lawsuit alleging Apple infringement of the same patents. AliveCor contends that Apple Inc. is infringing AliveCor’s asserted patents through the sale of Apple watches that employ infringing functionality. Filing in the ITC “is one step, among others, AliveCor is taking to obtain relief for Apple’s intentional copying of AliveCor’s patented technology—including the ability to take an ECG reading on the Apple Watch, and to perform heartrate analysis—as well as Apple’s efforts to eliminate AliveCor as competition in the heartrate analysis market for the Apple Watch.”
About AliveCor
AliveCor, Inc. is transforming cardiological care using deep learning. The FDA-cleared KardiaMobile device is the most clinically validated personal ECG solution in the world. KardiaMobile provides instant detection of Atrial Fibrillation, Bradycardia, Tachycardia, Sinus Rhythm with Supraventricular Ectopy, Sinus Rhythm with Premature Ventricular Contractions, Sinus Rhythm with Wide QRS and Normal Heart Rhythm. Kardia is the first AI-enabled platform to aid patients and clinicians in the early detection of atrial fibrillation, the most common arrhythmia and one associated with a highly-elevated risk of stroke. AliveCor's enterprise platform allows third party providers to manage their patients’ and customers’ heart conditions simply and profitably using state-of-the-art tools that provide easy front-end and back-end integration to AliveCor technologies. AliveCor protects its customers with stringent data security and compliance practices, achieving HIPAA compliance and SOC2 Type 1 and Type 2 attestations. AliveCor is a privately-held company headquartered in Mountain View, Calif. “Consumer” or “Personal” ECGs are ECG devices available for direct sale to consumers. For more information, alivecor.com.